ArticleRedox biology2025
A near-infrared fluorescent probe for dynamic HClO monitoring in epilepsy and high-throughput discovery of natural neuroprotectants.
Article in Redox biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Ratiometric Fluorescent Probe Based on Naphthalimide - Indole Scaffold for Imaging Hypochlorous Acid in Neuroin- Flammatory Models.Journal of fluorescence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epilepsy is a neurodegenerative disease closely associated with mitochondrial oxidative stress and neuronal damage, posing a grave threat to human health. Hypochlorous acid (HClO), a potent oxidant, has been demonstrated to play a critical role in the occurrence and progression of epilepsy. Accordingly, the development of a mitochondrial-targeted responsive HClO fluorescent probe could serve as a powerful tool for the early diagnosis of epilepsy and high-throughput screening (HTS) of natural neuroprotective. Herein, we report a mitochondria-targeted fluorescent probe (MB-Mito) with excellent selectivity, rapid activation kinetics, and blood-brain barrier (BBB) permeability, which is used for real-time and in situ tracking of HClO fluctuations in epilepsy models. More significantly, a visual HTS platform for natural neuroprotective agents was established based on MB-Mito, and an effective neuroprotective agent, myricetin, was identified from 47 natural compounds with potential antioxidant activity. Mechanistic studies have demonstrated that myricetin activates the ERK/Nrf2/HO-1 signaling pathway to mitigate mitochondrial oxidative stress, thereby providing precise treatment for epilepsy. All studies have confirmed that MB-Mito is a reliable tool for precise monitoring of HClO, drug HTS and mechanism research, promoting advances in the diagnosis and treatment of epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.